• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

C.P.M. Contract Pharma GmbH & Co. KG 9/17/13

  

Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 Silver Spring, MD  20993 

 

Warning Letter
           
WL: GDUFA-13-001
 
September 17, 2013
 
Dr. Uwe Reimers
Head of Production
C.P.M. Contract Pharma GMBH & Co. KG
Fruhlingstrasse 7
Feldkirchen-Westerham, Germany 83620
 
FEI: 3005466331
 
Dear Dr. Reimers:
 
The owner of the above referenced facility has failed to self-identify the facility and pay the appropriate facility fee as required by the Generic Drug User Fee Amendments of 2012 (GDUFA).   See 21 U.S.C. §§ 379j-41-379j-42.
 
GDUFA defines a facility in relevant part as “a business or other entity . . . at one geographic location or address engaged in manufacturing or processing an active pharmaceutical ingredient or a finished dosage form.” 21 U.S.C. §§ 379j-41(5)(A)(i)(II). If such a facility is identified or intended to be identified in a pending or approved generic drug submission, the person that owns that facility must submit information concerning the facility to FDA (self-identify) each year in accordance with 21 U.S.C. § 379j-42(f). Self-identification for fiscal year 2013 was required on or before December 3, 2012 and self-identification for fiscal year 2014 was required between May 1, 2013 and June 1, 2013.
 
If such a facility is identified or intended to be identified in a pending or approved generic drug submission on the facility fee due date, the person that owns that facility must pay an annual facility fee. 21 U.S.C. § 379j-42(a)(4). The fees for fiscal year 2013 were due on March 4, 2013. Only facilities that manufacture positron emission tomography drugs are exempted from this and other GDUFA fee requirements. See 21 U.S.C. § 379j-42(l). 
 
Any drugs or active pharmaceutical ingredients manufactured, prepared, propagated, compounded, or processed at a facility for which required facility fees have not been paid or required self-identifying information has not been submitted, or drugs containing an active pharmaceutical ingredient manufactured, prepared, propagated, compounded, or processed at such a facility are misbranded. 21 U.S.C. §§ 352(aa), 379j-42(g)(4)(iii). It is a violation of federal law to ship misbranded products in interstate commerce, which includes causing such products to be imported into the United States. 21 U.S.C. § 331(a). Such violations can result in injunctions or seizures of the misbranded products. See 21 U.S.C. §§ 332 and 334. Products that appear to be misbranded may also be denied entry into the United States. 21 U.S.C. § 381(a)(3).
 
Facilities that fail to pay the annual facility fee are placed on a publicly available arrears list. Any generic drug submission from the person responsible for paying the fee, or from an affiliate of that person, will not be received by FDA within the meaning of 21 U.S.C. § 355(j)(5)(A). In addition, any new generic drug submission that references such a facility will not be received, within the meaning of 21 U.S.C. § 355(j)(5)(A), if the outstanding facility fee is not paid within 20 calendar days of FDA providing notification to the sponsor of the failure of the owner of the facility to pay the facility fee. 21 U.S.C. § 379j-42(4)(ii).
 
The above-referenced facility is a drug manufacturing facility as defined under GDUFA. It was identified as a finished dosage form manufacturer in (b)(4) on the date for self-identification for fiscal year 2013 and fiscal year 2014 and on the due date for facility fees for fiscal year 2013, but has not self-identified or paid facility fees as required by that law. Therefore, all finished dosage forms of drugs or APIs, as well as drug containing an API, manufactured at the facility are misbranded.
 
Your facility has been placed on a publicly available arrears list. Failure to correct these violations promptly may result in regulatory action, including but not limited to seizure or injunction without further notice. Your facility may also be placed on import alert such that any drug the facility manufactures will be refused admission into the United States.
 
You should take prompt action to correct the violations noted above by immediately self-identifying and paying fiscal year 2013 fees immediately. Please note that because the fiscal year 2014 self-identification reporting period has begun, you will be unable to self-identify for fiscal year 2013. FDA will not take enforcement action against you or your products for failure to self-identify for fiscal year 2013 if you complete your 2014 self-identification submission within 15 working days of receipt of this notice. Information, including who is required to self-identify, how the information is submitted to FDA, who is required to pay facility fees, the penalty for failure to self-identify or to pay a facility fee, and the technical specifications for self-identification and fee payment, is available on FDA’s GDUFA webpage (www.fda.gov/gdufa).      
 
This letter is not intended to identify all of the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products marketed by your firm in United States commerce are in compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations.
 
Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken to correct the noted violations.  If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to:
 
GDUFACompliance @fda.hhs.gov
 
If email is not available, please send to:
 
David Mazyck
White Oak, Building 51, RM2260
10903 New Hampshire Ave.
Silver Spring, MD 20993
 
Sincerely,
/S/
Douglas Stearn
Deputy Director for Policy and Analysis
Office of Compliance
Center for Drug Evaluation and Research